| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Endocrinology, Metabolism, and Molecular Medicine and Northwestern University Medical School, Chicago, Illinois 60611
Address all correspondence and requests for reprints to: J. Larry Jameson, M.D., Ph.D., Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, Illinois 60611.
The ER plays an important role in the proliferation and differentiation of lactotrope tumor cells. GH4 cells were infected with adenoviral vectors (AdL540Q and Ad1–536) to investigate the ability of dominant negative ER mutants to affect the regulation of gene expression and cell growth by endogenous ER. The dominant negative mutants suppressed estradiol stimulation of an estrogen-responsive reporter gene and the PRL promoter in these cells. AdL540Q or Ad1–536 infection also inhibited GH4 cell growth and induced apoptosis, increasing the expression of the proapoptotic Bax protein and decreasing the expression of antiapoptotic Bcl-2. AdwtER-infected cells also showed decreased Bcl-2 protein. E2-induced activation of p38 MAPK, an enzyme that may participate in apoptosis, was observed in cells infected with AdwtER, AdL540Q, and Ad1–536. Consistent with the apoptotic effects in vitro, infection of GH4 cells with AdL540Q or Ad1–536 inhibited the ability of the cells to form tumors in nude mice. These results indicate that dominant negative ER mutants induce apoptosis of GH4 cells and suppress tumor formation and development. The delivery of dominant negative ERs by adenoviral vectors may provide an alternative modality for the targeted therapy of pituitary lactotrope adenomas and other estrogen-responsive tumors.
This article has been cited by other articles:
 |
|
 |
|
  M. H. Hassan, S. A. Salama, H. M. M. Arafa, F. M. A. Hamada, and A. Al-Hendy Adenovirus-Mediated Delivery of a Dominant-Negative Estrogen Receptor Gene in Uterine Leiomyoma Cells Abrogates Estrogen- and Progesterone-Regulated Gene Expression J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3949 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pellegrini, C. Roche, M.-H. Quentien, M. Ferrand, G. Gunz, S. Thirion, C. Bagnis, A. Enjalbert, and J.-L. Franc Involvement of the Pituitary-Specific Transcription Factor Pit-1 in Somatolactotrope Cell Growth and Death: An Approach Using Dominant-Negative Pit-1 Mutants Mol. Endocrinol., December 1, 2006; 20(12): 3212 - 3227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-G. Ren and S. Melmed Pyridoxal Phosphate Inhibits Pituitary Cell Proliferation and Hormone Secretion Endocrinology, August 1, 2006; 147(8): 3936 - 3942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Candolfi, G Jaita, D Pisera, L Ferrari, C Barcia, C Liu, J Yu, G Liu, M G Castro, and A Seilicovich Adenoviral vectors encoding tumor necrosis factor-{alpha} and FasL induce apoptosis of normal and tumoral anterior pituitary cells. J. Endocrinol., June 1, 2006; 189(3): 681 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ben-Jonathan Dopamine and Transforming Growth Factor-{beta}1: An Odd Couple in Growth Inhibition of the Lactotrophs Endocrinology, October 1, 2005; 146(10): 4177 - 4178. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Burdette, J. S. Jeruss, S. J. Kurley, E. J. Lee, and T. K. Woodruff Activin A Mediates Growth Inhibition and Cell Cycle Arrest through Smads in Human Breast Cancer Cells Cancer Res., September 1, 2005; 65(17): 7968 - 7975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Lee and J L. Jameson Gene therapy of pituitary diseases J. Endocrinol., June 1, 2005; 185(3): 353 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Candolfi, G. Jaita, V. Zaldivar, S. Zarate, L. Ferrari, D. Pisera, M. G. Castro, and A. Seilicovich Progesterone Antagonizes the Permissive Action of Estradiol on Tumor Necrosis Factor-{alpha}-Induced Apoptosis of Anterior Pituitary Cells Endocrinology, February 1, 2005; 146(2): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pisera, M. Candolfi, S. Navarra, J. Ferraris, V. Zaldivar, G. Jaita, M. G. Castro, and A. Seilicovich Estrogens sensitize anterior pituitary gland to apoptosis Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E767 - E771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Velardez, A. H. Poliandri, J. P. Cabilla, C. C. A. Bodo, L. I. Machiavelli, and B. H. Duvilanski Long-Term Treatment of Anterior Pituitary Cells with Nitric Oxide Induces Programmed Cell Death Endocrinology, April 1, 2004; 145(4): 2064 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watanabe, M. Akishita, T. Nakaoka, K. Kozaki, Y. Miyahara, H. He, Y. Ohike, T. Ogita, S. Inoue, M. Muramatsu, et al. Estrogen receptor {beta} mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation Cardiovasc Res, September 1, 2003; 59(3): 734 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paez-Pereda, D. Giacomini, D. Refojo, A. C. Nagashima, U. Hopfner, Y. Grubler, A. Chervin, V. Goldberg, R. Goya, S. T. Hentges, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk PNAS, February 4, 2003; 100(3): 1034 - 1039. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
